Diabetes Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Diabetes Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Diabetes Control

Insulin glargine plus oral hypoglycemic agents provide glycemic control in type 2 diabetes

"This study examined the long-term glycemic control and safety of insulin glargine (LANTUS) in patients with type 2 diabetes. This {{<=}}28-month, long-term extension of a multinational, multicenter, open-label 52-week study enrolled patients from the original study to continue taking insulin glargine at bedtime plus previous oral hypoglycemic agents (OHAs). Efficacy and safety were assessed by HbA_1c and adverse events, symptomatic hypoglycemia and selected clinical and laboratory variables," investigators in Austria report.

G....

• View Other Issues of Diabetes Week
  
• View Other NewsRx Publications